Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study.

Abstract

To investigate the safety and efficacy of botulinum toxin type A (BoNTX) treatment to reduce sialorrhea in Parkinson's disease (PD), a double-blind, randomized, placebo-controlled study enrolled 32 PD patients complaining of excessive drooling. Patients received either 50 U Botox in each parotid gland or placebo without using ultrasound guidance. Subjects treated with BoNTX experienced a reduction in both drooling frequency and familial and social disability (TimexGroup effect: P<0.01), as well as in saliva production (Time x Group effect: P<0.0001). No adverse events were recorded. BoNTX injections are safe and effective treatment for the management of PD-related drooling.

• Authors: Giovanni Lagalla, Marzia Millevolte, Marianna Capecci, Leandro Provinciali, Maria Gabriella Ceravolo
• Journal: Movement disorders : official journal of the Movement Disorder Society (Mov Disord) Vol. 21 Issue 5 Pg. 704-7 (May 2006) ISSN: 0885-3185 [Print] United States
• PMID: 16440332 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
• Copyright: Copyright (c) 2006 Movement Disorder Society.

Chemical References

• Neuromuscular Agents
• Botulinum Toxins, Type A

Topics

• Aged
• Botulinum Toxins, Type A (therapeutic use)
• Double-Blind Method
• Female
• Humans
• Male
• Middle Aged
• Neuromuscular Agents (therapeutic use)
• Parkinson Disease (complications, drug therapy, physiopathology)
• Sialorrhea (drug therapy, etiology)